ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Ide-cel provides lasting remissions in multiply-relapsed myeloma
February 26, 2021BMS and bluebird bio have applied to the FDA for approval of ide-cel as a standard therapy for relapsed or refractory multiple myeloma based on positive Phase II trial results. -
Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel for Adults with Relapsed and Refractory Multiple Myeloma
September 23, 2020Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc. (Nasdaq: BLUE) today announced the submission of their Biologics License Application (BLA) to the U.S. -
Bristol Myers Squibb and bluebird bio submit BLA for Idecabtagene Vicleucel to FDA
April 03, 2020Bristol Myers Squibb and bluebird bio submitted their Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA).
Pharma Sources Insight January 2025
